Alessa Therapeutics, a San Carlos, CA-based clinical-stage drug development company, raised $15M in Seed funding.
The round was led by Mission BioCapital, with participation from Johnson & Johnson.
The company intends to use the funds to advance development of its lead program, EnolenĀ®, a novel enzalutamide-eluting seed implant for the treatment of localized prostate cancer.
Led by CEO and Founder Pamela Munster, Alessa Therapeutics is focused on developing selective and sustained localized drug delivery for early interception of cancer. Its proprietary localized drug-delivering implants are designed for sustained release of an anti-androgen selectively to the prostate thus limiting systemic side effects despite providing therapeutic concentrations in the prostate.Ā
FinSMEs
13/12/2024